- Nuformix, which uses cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, said it had commenced clinical studies for its lead asset.

The asset, NXP001, was in development as a treatment for chemotherapy-induced nausea and vomiting.

First dosing took place on 20 March in a cross-over study that aimed to measure the relative bioavailability of NXP001 compared to Merck's EMEND in healthy subjects.

Dosing would complete during April 2019 with results expected by end of the first half of 2019.

Story provided by